Method of treating or preventing tumors of the central nervous system
Inventors
Jimenez, Joaquin J. • Narain, Niven Rajin • Sarangarajan, Rangaprasad • McCook, John Patrick
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11452699-B2
Publication Date
2022-09-27
Expiration Date
Abstract
The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor.
Core Innovation
The invention provides methods and compositions using Coenzyme Q10 (CoQ10) to treat or prevent primary or metastatic central nervous system (CNS) tumors. The treatment is for a subject exhibiting at least one CNS abnormality as a result of the presence of the CNS tumor, with decreased muscle control as an abnormality, and treatment results in amelioration of the decreased muscle control in the subject.
The invention further addresses secondary CNS tumor development arising from a primary tumor. CoQ10 administration is described as treating a secondary CNS tumor in a subject exhibiting at least one CNS abnormality due to the secondary CNS tumor, with decreased muscle control included among the abnormalities, and prophylactic CoQ10 administration after remission is proposed to reduce incidence or latency of secondary CNS tumors.
The described scope includes CNS tumors and CNS abnormalities, including decreased muscle control, paralysis, and other neurological and cognitive deficits. Example data in Fischer 344 rats are described as showing improved motor function, reduced or paradoxical absence of CNS tumor lesions on MRI, reduced mortality, and sustained long-term effects with CoQ10 versus controls.
Claims Coverage
The provided independent claims cover two treatment methods. Each independent claim centers on CoQ10 administration linked to amelioration of decreased muscle control as the core inventive effect, and the overall claim set includes additional refined contexts and constraints in dependent claims.
CoQ10 treatment of a CNS tumor linked to amelioration of decreased muscle control
A method of treating a central nervous system (CNS) tumor in a subject exhibiting at least one CNS abnormality as a result of the presence of the CNS tumor by administering a composition comprising a Coenzyme Q10 (CoQ10) compound, wherein the at least one CNS abnormality comprises decreased muscle control, and wherein treatment results in amelioration of the decreased muscle control.
CoQ10 treatment of a secondary CNS tumor linked to amelioration of decreased muscle control
A method of treatment of a secondary CNS tumor from a primary tumor in a subject exhibiting at least one CNS abnormality as a result of the presence of the secondary CNS tumor by administering a composition comprising a Coenzyme Q10 (CoQ10) compound, wherein the at least one CNS abnormality comprises decreased muscle control, and wherein treatment results in amelioration of the decreased muscle control.
Across the independent claims, the inventive focus is administering a CoQ10-containing composition to treat a CNS tumor or a secondary CNS tumor, with decreased muscle control as the defining CNS abnormality and with treatment resulting in amelioration of the decreased muscle control.
Stated Advantages
Amelioration of decreased muscle control in the subject after treatment.
Treatment of the CNS tumor or the secondary CNS tumor.
Reduced or paradoxical absence of CNS tumor lesions on MRI is described in the document.
Reduced mortality and sustained long-term effects with CoQ10 versus controls are described in the document.
Documented Applications
Treating a primary or secondary central nervous system (CNS) tumor in a subject exhibiting CNS abnormalities including decreased muscle control.
Preventing or reducing incidence or latency of secondary CNS tumors by prophylactic CoQ10 administration after remission is proposed in the document.
Use cases tied to CNS abnormalities including decreased muscle control, paralysis, and other neurological and cognitive deficits.
Interested in licensing this patent?